Skip to main content
Midas Edge

Akebia Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

AKBA$0.53+32.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AKEBIA THERAPEUTICS, INC.
Date: March 13, 2025By:/s/ John P. Butler
John P. Butler
President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the registrant and in the capacities and on the date indicated.

Date: March 13, 2025By:/s/ John P. Butler
John P. Butler
Director, President and Chief Executive Officer (Principal Executive Officer)
Date: March 13, 2025By:/s/ Erik J. Ostrowski
Erik J. Ostrowski
Senior Vice President, Chief Financial Officer and Chief Business Officer (Principal Financial Officer)
Date: March 13, 2025/s/ Richard C. Malabre
Richard C. Malabre
Senior Vice President, Chief Accounting Officer (Principal Accounting Officer)
Date: March 13, 2025By:/s/ Adrian Adams
Adrian Adams
Chairperson and Director
Date: March 13, 2025By:/s/ Ron Frieson
Ron Frieson
Director
Date: March 13, 2025By:/s/ Steven C. Gilman
Steven C. Gilman
Director
Date: March 13, 2025By:/s/ Michael Rogers
Michael Rogers
Director
Date: March 13, 2025By:/s/ Cynthia Smith
Cynthia Smith
Director
Date: March 13, 2025By:/s/ Myles Wolf
Myles Wolf
Director
Date: March 13, 2025By:/s/ LeAnne M. Zumwalt
LeAnne M. Zumwalt
Director
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.